NICOLA HANANIA to Follow-Up Studies
This is a "connection" page, showing publications NICOLA HANANIA has written about Follow-Up Studies.
Connection Strength
0.220
-
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
Score: 0.065
-
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
Score: 0.049
-
Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With?Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort. Chest. 2023 02; 163(2):292-302.
Score: 0.027
-
The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
Score: 0.019
-
Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 02 01; 195(3):324-330.
Score: 0.018
-
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
Score: 0.016
-
Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
Score: 0.015
-
Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
Score: 0.010